
ABSTRACT Background Rates of young‐onset colorectal cancer (CRC) are on the rise globally. Despite this growing burden, the drivers of young‐onset adult CRC remain largely unknown. Aims This study aimed to compare risk factor profiles between younger‐onset and late‐onset CRC to evaluate differences in their risk factor profiles. Methods The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial dataset, comprising ∼155,000 US participants including 1219 CRC cases, was analysed. Participants were stratified by age (≤59 vs. ≥60 years). Associations of demographic, clinical and behavioural risk factors with CRC were computed using multivariable Cox regression with the multiplicative interaction of exposures. Reduced rank regression was used to derive dietary patterns (DPs). Results Among the ≤59‐year cohort, no individual risk factor (excluding age) was independently associated with the risk of CRC. However, the multiplicative effect of hypertension and smoking had a nominal association with younger‐onset CRC ( p = 0.047). In contrast, in the ≥60‐year cohort, individual (sex, body mass index, diabetes and alcohol) as well as combinations of risk factors were associated with CRC. Significant DPs appeared exclusively to impact the risk of CRC in the ≥60‐year cohort. However, no interactions remained significant following correction for multiple testing; findings should be interpreted as hypothesis‐generating. Conclusions These findings suggest that the drivers of CRC in younger individuals may be different from their older counterparts. These exploratory findings offer novel insight into CRC risk in the young and highlight the need to reconsider interactions between CRC risk factors.
Locally advanced rectal cancer (LARC) often requires aggressive multimodal therapy, yet pathological complete response (pCR) to standard chemoradiotherapy remains low. Transarterial chemoembolization (TACE) enables targeted locoregional delivery of chemotherapy to tumor-feeding arteries, and its recent extension, chemo-immunoembolization, permits intraarterial delivery of immune checkpoint inhibitors. This updated systematic review searched MEDLINE, EMBASE, and Web of Science from inception to June 2026 for studies of TACE or transcatheter rectal arterial chemoembolization (TRACE) in LARC, with quality appraised using the Newcastle-Ottawa Scale. Nine studies encompassing 822 patients, 582 of whom received TACE or TRACE, were included, predominantly from China; one further trial is ongoing. pCR rates ranged from 10% to 44.74%. In comparative studies, TRACE with oxaliplatin was associated with lower tumor regression grade 3 (TRG3) rates, reaching significance in the largest comparison, and with a survival benefit in an exploratory TRG3 subgroup analysis, suggesting a possible role in chemoradiotherapy-resistant disease. The highest pCR occurred in a phase II trial of intra-arterial tislelizumab plus TACE in mismatch repair-proficient LARC, with no grade 3-4 immune-related adverse events. Major complications were uncommon. TACE may improve pathological response with an acceptable safety profile in LARC, although comparative evidence is limited and non-randomized; CIETAI provides first-in-human proof-of-concept for intra-arterial delivery of immunotherapy.